Message #14 From:
Stock News Bot Date: December 18, 2006 05:30:00 AM
ADXS News Advaxis Names Thomas A. Moore to Serve as CEO and Chairman of the Board
NORTH BRUNSWICK, N.J.--(BUSINESS WIRE)--Advaxis, Inc. (OTCBB: ADXS) a biotechnology company developing novel Listeria-based
therapeutic cancer vaccines, announced that its Board of Directors has
named Thomas A. Moore to serve as the company's Chief Executive Officer
and Chairman. Mr. Moore replaces Roni Appel as CEO, who will remain on
the Board of Directors and continue to work closely with Mr. Moore as an
advisor to the company.
Moore, 55, who has served on the Advaxis Board of Directors since
September 2006 brings more than 25 years of experience in healthcare and
general management. Mr. Moore is currently a board member of Alteon,
Inc., a publicly traded developer of pharmaceuticals for the treatment
of diabetes and age-related diseases, El Dorado Inc., a targeted
marketer to unassimilated Hispanics, Medmeme, which measures medical
education effectiveness, and Opt-e-scrip, Inc., which markets a clinical
system to compare multiple drugs in the same patient. He also serves as
Chairman of Mayan Pigments, Inc., which has developed and patented Mayan
pigment technology. Previously, from June 2002 to June 2004 Mr. Moore
was President and Chief Executive Officer of Biopure Corporation, a
developer of oxygen therapeutics that are intravenously administered to
deliver oxygen to the body’s tissues. From
1996 to November 2000 he was President and Chief Executive Officer of
Nelson Communications. Previously, Mr. Moore had a 23-year career with
the Procter & Gamble Company in multiple managerial positions, including
President of Health Care Products where he was responsible for
prescription and over-the-counter medications worldwide, and Group Vice
President of the Procter & Gamble Company.
Mr. Moore said, “I have had the pleasure of
working with the Advaxis team over the past few months and look forward
to helping set the future direction of Advaxis. The company is
developing novel and exciting vaccine therapies and I believe it has a
solid future. I am pleased to have the opportunity to be working closely
with such a talented group of scientific and business leaders.”
Mr. Appel said, “My fundamental passion is
guiding companies through their initial growth. When I co-founded
Advaxis with Dr. Yvonne Paterson, Professor of Molecular Biology at
University of Pennsylvania, we had the vision of developing an
immunotherapy that would fundamentally change the way cancer is treated.”
Mr. Appel continued, “Since beginning
operations, Advaxis has recruited an outstanding management team,
secured funding, scaled up its manufacturing capabilities, established
its own laboratories and hired a group of top level scientists to
complement the founding team. The company has now nine Listeria-based
cancer vaccines in development, with its lead vaccine Lovaxin C in Phase
I/II currently dosing cancer patients. As a team, we have built a very
strong company poised for substantial growth in the fast-advancing field
of cancer vaccines. I am committed to working with the board and Mr.
Moore during this transition, and I have utmost confidence in Advaxis’
future success under the leadership of Mr. Moore."
"We want to thank Roni for his leadership during an important and
challenging phase of Advaxis’ corporate growth
and development," stated Richard Berman, Director of Advaxis. "Roni has
been instrumental in positioning the company for success, with its lead
Listeria cancer vaccine Lovaxin C and many of the components of a
fully integrated biopharmaceutical company in place. Mr. Moore is a
seasoned and highly respected pharmaceutical executive with over 25
years of experience in researching, developing and commercializing
biopharmaceutical products. We are pleased to have a person of Mr. Moore’s
caliber on our management team to step in and lead the company during
the next phase of the company’s growth."
About Advaxis
Based in North Brunswick, New Jersey. Advaxis is developing proprietary
Listeria cancer vaccines based on technology developed by Dr. Yvonne
Paterson, professor of microbiology at the University of Pennsylvania,
and chair person of Advaxis' Scientific Advisory Board. Advaxis' is
developing therapeutic cancer vaccines that enhance the immune system's
cancer-fighting abilities through its proprietary Listeria monocytogenes
based system, which utilizes two immunological mechanisms (Innate and
Classical Immunity) to develop safer and more effective Listeria based
cancer vaccines. Advaxis is the exclusive licensee of a patented broadly
enabling Listeria platform technology that can elicit effective
anti-tumor responses. Advaxis' lead Listeria vaccine candidate, Lovaxin
C, targets cervical and head and neck cancers. Further Listeria vaccines
in development target breast, ovarian and lung cancers. Advaxis has
entered a Phase I/II clinical trial. The Listeria platform will also
have applications in the fields of infectious disease and autoimmune
disorders.
Forward Looking Statements
Certain statements contained in this press release are forward looking
statements that involve risks and uncertainties. The statements
contained herein that are not purely historical are forward looking
statements within the meaning of Section 27A of the Securities Act of
1933, as amended and Section 21E of the Securities Exchange Act of 1934,
as amended. Forward looking statements deal with the Company's current
plans, intentions, beliefs and expectations and statements of future
economic performance. Forward looking statements involve known and
unknown risks and uncertainties that may cause the Company's actual
results in future periods to differ materially from what is currently
anticipated. Factors that could cause or contribute to such differences
include those discussed from time to time in reports filed by the
Company with the Securities and Exchange Commission. The Company cannot
guarantee its future results, levels of activity, performance or
achievements.
